29 March 2021
Urgent amendment of the sartan monographs in the European Pharmacopoeia
The five revised monographs on sartans with a tetrazole ring, candesartancilexetil, irbesartan, losartan potassium, olmesartan medoxomil and valsartan, will enter into force on 1 April 2021. These revised monographs have not been published in Pharmeuropa for public inspection as the changes made are in line with the CHMP recommendations.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar